- Open Access
Association between TNFAIP3 nonsynonymous single-nucleotide polymorphism rs2230926 and chronic hepatitis B virus infection in a Chinese Han population
© Zhang et al.; licensee BioMed Central. 2015
- Received: 6 January 2015
- Accepted: 18 February 2015
- Published: 28 February 2015
Single-nucleotide polymorphisms (SNPs) in tumor necrosis factor alpha-inducible protein 3 (TNFAIP3) gene have been linked to inflammatory, immunological and malignant diseases. Hepatitis B virus (HBV) infection is characterized by immunopathogenesis. This study investigated the association of rs2230926, a nonsynonymous SNP in TNFAIP3 gene, with chronic HBV infection.
Four hundred and fifty-five patients with chronic HBV infection with clinical diseases of chronic hepatitis (n = 183), liver cirrhosis (n = 167) and hepatocellular carcinoma (n = 105), 92 HBV infection resolvers and 171 healthy controls were included. All subjects were of Chinese Han ethnicity. Genotyping of rs2230926 was carried out by polymerase chain reaction-restriction fragment length polymorphism method.
The gender and age between HBV patients, HBV infection resolvers and healthy controls had no statistical difference. The genotypes of rs2230926 in HBV patients, HBV infection resolvers and healthy controls are in Hardy-Weinberg equilibrium. The genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients, HBV infection resolvers and healthy controls had no significant difference. The genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma also showed no significant difference.
The TNFAIP3 rs2230926 polymorphism is not suggested to be associated with the susceptibility of chronic HBV infection or the progression of HBV-related diseases in this study. Replicative studies and studies in large control and HBV patient populations of different ethnicity by genotyping more polymorphisms in TNFAIP3 gene are needed.
- Hepatitis B virus
- Clinical disease
Hepatitis B virus (HBV) infection is a major cause of liver disease. Globally, two billion people have been infected with HBV, 360 million have chronic infection, and 600,000 die each year from HBV-related liver diseases including liver cirrhosis and hepatocellular carcinoma (HCC) . The development and progress of HBV-associated liver disease is regarded as a result of the interplay between the virus and the host’s immune response [2,3]. The intensity of immuno-inflammatory responses of the hosts to various levels of the HBV viral replication characterizes the natural course of chronic HBV infection and has been extensively studied, showing that immunoinflammatory responses associated with various types of cells are involved in the course [4-9]. In particular, T cell exhaustion, which is characterized by a hierarchical and progressive loss of T-cell functions , is a significant feature of chronic HBV infection. Up-regulation of inhibitory molecules and down-regulation of effector function are characteristics of the exhaustion of HBV-specific T cells [11,12]. Because the excess of inhibitory molecules is among the critical factors driving T cell exhaustion in chronic HBV infection, blockade of these inhibitory molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and T-cell immunoglobulin domain and mucin domain-containing molecule-3 (Tim-3) has been demonstrated to reconstitute the potential of functional HBV-specific T cells [11,12]. Genetically, single-nucleotide polymorphisms (SNPs) in PD1 , CTLA4  and TIM3  have also been demonstrated to be associated with the disease progression of chronic HBV infection. However, the role of these molecules in chronic HBV infection appeared to be non-redundant and the rescue of HBV T cell specificities by their blockade was incomplete and not all patients responded to these strategies, suggesting the possible role of other inhibitory molecules.
Tumor necrosis factor alpha-inducible protein 3 (TNFAIP3, also known as A20), a cytoplasmic zinc finger protein with ubiquitin-modifying activity, has been identified as a negatively regulating molecule that inhibits nuclear factor kappa-B (NF-κB) activity and tumor necrosis factor (TNF)-mediated programmed cell death [16-19]. Human genetic studies have linked polymorphisms in the TNFAIP3 gene to inflammatory, autoimmune and malignant diseases . Among the SNPs in TNFAIP3 gene, rs2230926, a nonsynonymous common coding SNP in exon 3 of TNFAIP3 which introduces the amino acid substitution of phenylalanine to cysteine at amino acid position 127 of the protein, has been functionally shown to possibly influence the mRNA expression of TNFAIP3 and the inhibitory activity of TNFAIP3 [21-23]. Furthermore, TNFAIP3 rs2230926 polymorphism has been demonstrated to be significantly associated with systemic lupus erythematosus (SLE) among multiple ethnic populations [21,24-29] and other autoimmune diseases such as Sjögren’s syndrome, Crohn’s disease, psoriasis and rheumatoid arthritis [30,31].
The possible role of TNFAIP3 in chronic HBV infection remains largely unknown. Given the functional relevance, the common frequency and the strong association with immune-associated diseases of rs2230926 polymorphism in the TNFAIP3 gene as well as the involvement of immunoregulatory and inflammatory responses in chronic HBV infection, the aim of this study was to examine the possible association between TNFAIP3 rs2230926 polymorphism and chronic HBV infection in a Chinese Han population.
Patients and controls
Demographics and Hardy-Weinberg equilibrium of the genotypes of rs2230926 G/T polymorphism in HBV patients, HBV infection resolvers and healthy controls and the clinical diagnosis of HBV patients
Patients ( n = 455)
Resolvers ( n = 92)
Controls ( n = 171)
Age [year, mean ± SD (range)]
41.8 ± 13.2 (18–77)
44.3 ± 15.1 (18–78)
42.7 ± 15.8 (19–76)
HWE (observed vs. expected, P value)
Determination of serum HBV markers and liver biochemistry
Serum HBV markers including HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were detected using ELISA from Beijing Wantai Biological Pharmacy (Beijing, China). Biochemical liver function including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (IU/L) was assayed on the Olympus AU5400 automatic biochemical analyzer (Olympus Corporation, Mishama, Japan). Serum HBV DNA levels (IU/ml) were quantitatively determined using hepatitis B virus fluorescence polymerase chain reaction diagnostic kit manufactured by Da An Gene Co., Ltd. of Sun Yat-Sen University (Guangzhou, China) according to the instruction. Serum AFP levels (ng/ml) were measured using automated Eleceyes (Roche Diagnostics, Mannheim, Germany).
Genotyping of TNFAIP3 rs2230926 polymorphism
Genomic DNA was extracted from EDTA-treated peripheral blood using TIANamp Genomic DNA Kit [Tiangen Biotech (Beijing) Co., Ltd., Beijing, China] according to manufacturer’s instruction. Genotyping of TNFAIP3 rs2230926 G/T polymorphism was carried out by DNA amplifications with polymerase chain reaction (PCR) and specific primer sets, followed by the restriction fragment length polymorphism (RFLP) method. The primers used for amplification are: Forward: (12169–12188) 5′-CTCCTTTGCAGTTGGTGTCA-3′ and Reverse: (12698–12717) 5′-GCTTCGCTTAGCCAAATTCA-3′ , according to TNFAIP3 sequence (NG_032761). The PCR was carried out in a volume of 25 μl reaction, containing 12.5 μl 2 × Taq plus PCR Mix (Xi’an Runde Biotechnology, Xi’an, China),1.0 μl (10 μM) forward primer, 1.0 μl (10 μM) reverse primer, 6 μl genomic DNA and 4.5 μl sterile double distilled water. The reaction mixture was pre-heated at 94°C for 5 min, then amplified 30 cycles using the following program: heated at 94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 1 min, and lastly extended at 72°C for 10 min. The undigested PCR product has a length of 549 bp. The restriction fragments of the polymorphism were obtained using restriction endonuclease Fnu4HI [New England Biolabs (Beijing) Ltd., Beijing, China] according to the instruction of the manufacturer. The Fnu4HI has a restriction site on the PCR products with G allele (12486–12490, TCAGC > GCAGC). Digested fragments were analyzed by electrophoresis on 2% agarose gels stained with ethidium bromide. The genotypes of the polymorphism were determined according to the digestion patterns: genotype TT: a fragment of 549 bp, genotype GT: 3 fragments of 549 bp, 319 bp and 230 bp, respectively, and genotype GG: 2 fragments of 319 bp and 230 bp, respectively.
Statistical analysis was performed by SPSS software version 16.0 (SPSS, Inc., Chicago, IL). The frequency of genotypes and alleles was determined by direct gene counting method. Hardy-Weinberg equilibrium of the polymorphism was tested with χ2 test. The association between polymorphism and disease status was tested using χ2 test for contingency tables or Fisher’s exact test where applicable . Odds ratios (OR) and its 95% confidence interval (CI) were calculated to estimate the risk conferred by a particular genotype and allele. A P value < 0.05 was considered statistically significant.
Ethical approval and consent
This study was approved by the Review Board of the First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the participants for the publication of this report.
Demographics and Hardy-Weinberg equilibrium of the genotypes of rs2230926 in the study subjects
The demographics of the study subjects and the clinical diagnosis of the HBV patients are presented in Table 1. All subjects were of Chinese Han ethnicity. The gender and age between HBV patients, HBV infection resolvers and healthy controls had no statistical difference (Table 1). The genotypes of rs2230926 in HBV patients, HBV infection resolvers and healthy controls are in Hardy-Weinberg equilibrium (P > 0. 05, Table 1).
Genotype and allele frequencies of rs2230926 polymorphism in hepatitis B virus (HBV) patients, HBV infection resolvers and healthy controls
Genotype and allele frequencies of the rs2230926 G/T polymorphism in hepatitis B virus (HBV) patients, HBV infection resolvers and healthy controls
Patients vs. resolvers
Patients vs. controls
Resolvers vs. controls
( n = 455)
( n = 92)
( n =171)
OR (95% CI)
OR (95% CI)
OR (95% CI)
1.55 (0.69- 3.47)
Genotype and allele frequencies of rs2230926 polymorphism in hepatitis B virus (HBV) patients with different clinical diagnosis
Genotype and allele frequencies of rs2230926 G/T polymorphism in hepatitis B virus (HBV) patients with different clinical diagnosis
Chronic hepatitis vs. Cirrhosis
Chronic hepatitis vs. HCC
Cirrhosis vs. HCC
( n = 183)
( n = 167)
( n = 105)
OR (95% CI)
OR (95% CI)
OR (95% CI)
358 (97. 8)
1.62 (0.63- 4.14)
8 (2. 2)
This study investigated the possible association of TNFAIP3 nonsynonymous SNP rs2230926 with chronic HBV infection in Chinese Han population. The genotype and allele frequencies of rs2230926 polymorphism in the healthy control population of this study were: genotype TT, 95.91%; genotype GT, 4.09%; allele T, 97.95%; and allele G, 2.05%. Considering the minor allele, the allele G in this study was lower than other studies in Chinese Han populations (4.5%-5.9%) [27,34] and Korean population (5.3%) . Although studies in Chinese Han population revealed very low frequency of genotype GG (0.091%-0.3%) [27,34], we did not detect genotype GG in both the control and patient populations and this is consistent with the findings in Korean population . These results indicate that the rs2230926 polymorphism may vary greatly even in populations with genetic vicinity.
This study showed that the genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients, HBV infection resolvers and healthy controls and among HBV patients with different clinical diagnosis had no significant differences, suggesting that this polymorphism might not contribute to the susceptibility of chronic HBV infection or the progression of HBV-related diseases. Previous studies showed that this polymorphism is associated with other diseases especially autoimmune disorders [21,24-31]. It is therefore suggested that the significance of this genetic polymorphism might be restricted to specific diseases.
It is noteworthy that recent studies proposed that a pair of tandem polymorphic dinucleotides (rs148314165, rs200820567, referred to as TT > A) located in the genomic DNA 30 kb telomeric of TNFAIP3 may be the most likely candidate variants responsible for association with SLE and the TT > A risk alleles are carried on a risk haplotype that is associated with hypomorphic expression of TNFAIP3 transcripts and protein and the TT > A risk variants attenuate TNFAIP3 expression through inefficient delivery of NF-kB to the TNFAIP3 promoter [36,37], evidencing the critical functional role of TT > A in the genetic predisposition to autoimmune diseases. Therefore, considering the relevance of TNFAIP3 molecule to the regulation of NF-κB activity and TNF-mediated programmed cell death [16-19] and the involvement of NF-κB activity and programmed cell death in HBV infection [38-40], the possible predisposition effect of this TT > A polymorphism in chronic HBV infection deserves investigation in future studies.
It should be noted that this study has limitations. The findings were preliminary results from a limited number of HBV patients and controls of Chinese Han population. The study only analyzed the association of one polymorphism with cross-sectional diseases in chronic HBV infection. The lack of replicative patient and control populations also compromised the probative value of the findings. Therefore, further studies in large patient and control populations of different ethnicity with longitudinal follow-up of the patients by genotyping more polymorphisms in TNFAIP3 gene are needed to clarify the possible effect of TNFAIP3 polymorphisms on chronic HBV infection and HBV-related diseases.
This work was supported in part by funding from the National Natural Science Foundation of China (Grant no. 81371798). We thank Dr. Guoyu Zhang and Dr. Zhu Li for their assistance in this study.
- Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–25.View ArticlePubMedGoogle Scholar
- Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis. 2004;24 Suppl 1:3–10.View ArticlePubMedGoogle Scholar
- Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000;192:921–30.View ArticlePubMed CentralPubMedGoogle Scholar
- Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009;58:974–82.View ArticlePubMedGoogle Scholar
- TrehanPati N, Geffers R, Sukriti, Hissar S, Riese P, Toepfer T, et al. Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology. 2009;49:781–90.View ArticlePubMedGoogle Scholar
- Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 2008;205:2111–24.View ArticlePubMed CentralPubMedGoogle Scholar
- Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 2009;126:280–9.View ArticleGoogle Scholar
- Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41:771–8.View ArticlePubMedGoogle Scholar
- Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129:474–81.View ArticlePubMed CentralPubMedGoogle Scholar
- Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138:682–93. 693 e681-684.View ArticlePubMedGoogle Scholar
- Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011;53:1494–503.View ArticlePubMedGoogle Scholar
- Zhang G, Liu Z, Duan S, Han Q, Li Z, Lv Y, et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol. 2010;71:1209–13.View ArticlePubMedGoogle Scholar
- Duan S, Zhang G, Han Q, Li Z, Liu Z, Chen J, et al. CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with −318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol Biol Rep. 2011;38:5125–32.View ArticlePubMedGoogle Scholar
- Li Z, Liu Z, Zhang G, Han Q, Li N, Zhu Q, et al. TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: impact on disease susceptibility and hepatocellular carcinoma traits. Tissue Antigens. 2012;80:151–7.View ArticlePubMedGoogle Scholar
- Jaattela M, Mouritzen H, Elling F, Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol. 1996;156:1166–73.PubMedGoogle Scholar
- Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289:2350–4.View ArticlePubMed CentralPubMedGoogle Scholar
- Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5:1052–60.View ArticlePubMedGoogle Scholar
- Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity. 2008;28:381–90.View ArticlePubMed CentralPubMedGoogle Scholar
- Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012;12:774–85.View ArticlePubMed CentralPubMedGoogle Scholar
- Kawasaki A, Ito I, Ito S, Hayashi T, Goto D, Matsumoto I, et al. Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population. J Biomed Biotechnol. 2010;2010:207578.View ArticlePubMed CentralPubMedGoogle Scholar
- Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.View ArticlePubMedGoogle Scholar
- Song GG, Bae SC, Lee YH. Pathway analysis of genome-wide association studies on rheumatoid arthritis. Clin Exp Rheumatol. 2013;31:566–74.PubMedGoogle Scholar
- Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40:1062–4.View ArticlePubMed CentralPubMedGoogle Scholar
- Lee YH, Song GG. Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis. Genet Test Mol Biomarkers. 2012;16:1105–10.View ArticlePubMedGoogle Scholar
- Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, et al. The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 2010;62:574–9.View ArticlePubMedGoogle Scholar
- Cai LQ, Wang ZX, Lu WS, Han JW, Sun LD, Du WH, et al. A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population. Mol Biol Rep. 2010;37:389–94.View ArticlePubMedGoogle Scholar
- Cen H, Zhou M, Leng RX, Wang W, Feng CC, Li BZ, et al. Genetic interaction between genes involved in NF-kappaB signaling pathway in systemic lupus erythematosus. Mol Immunol. 2013;56:643–8.View ArticlePubMedGoogle Scholar
- Fan Y, Tao JH, Zhang LP, Li LH, Ye DQ. The association between BANK1 and TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis. Int J Immunogenet. 2011;38:151–9.View ArticlePubMedGoogle Scholar
- Musone SL, Taylor KE, Nititham J, Chu C, Poon A, Liao W, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun. 2011;12:176–82.View ArticlePubMed CentralPubMedGoogle Scholar
- Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res. 2012;61:635–41.View ArticlePubMedGoogle Scholar
- Zagoriti Z, Georgitsi M, Giannakopoulou O, Ntellos F, Tzartos SJ, Patrinos GP, et al. Genetics of myasthenia gravis: a case–control association study in the Hellenic population. Clin Dev Immunol. 2012;2012:484919.View ArticlePubMed CentralPubMedGoogle Scholar
- Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8.View ArticlePubMedGoogle Scholar
- Zhang X, Li W, Zhao L, Jiang L, Guo Y, Zhang J, et al. Single nucleotide polymorphisms in TNFAIP3 were associated with the risks of rheumatoid arthritis in northern Chinese Han population. BMC Med Genet. 2014;15:56.View ArticlePubMed CentralPubMedGoogle Scholar
- Kim SK, Choe JY, Bae J, Chae SC, Park DJ, Kwak SG, et al. TNFAIP3 gene polymorphisms associated with differential susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Korean population. Rheumatology (Oxford). 2014;53:1009–13.View ArticleGoogle Scholar
- Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43:253–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Wang S, Wen F, Wiley GB, Kinter MT, Gaffney PM. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet. 2013;9:e1003750.View ArticlePubMed CentralPubMedGoogle Scholar
- Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol. 2003;77:4033–42.View ArticlePubMed CentralPubMedGoogle Scholar
- Satake S, Nagaki M, Kimura K, Moriwaki H. Inhibition of nuclear factor-kappa B induces inflammatory cell migration and exacerbates severe liver injury in hepatitis B virus transgenic mice. Hepatol Res. 2007;37:524–30.View ArticlePubMedGoogle Scholar
- Clippinger AJ, Gearhart TL, Bouchard MJ. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore. J Virol. 2009;83:4718–31.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.